217 related articles for article (PubMed ID: 24818961)
1. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E; Lewis KM; Vink R; Ghabriel MN
Neuroscience; 2014 Mar; 261():85-94. PubMed ID: 24374326
[TBL] [Abstract][Full Text] [Related]
3. NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Leonard AV; Thornton E; Vink R
PLoS One; 2014; 9(5):e98364. PubMed ID: 24859234
[TBL] [Abstract][Full Text] [Related]
4. Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours.
Lewis KM; Harford-Wright E; Vink R; Ghabriel MN
J Neuroimmunol; 2012 Sep; 250(1-2):59-65. PubMed ID: 22722013
[TBL] [Abstract][Full Text] [Related]
5. NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer.
Lewis KM; Harford-Wright E; Vink R; Ghabriel MN
Anticancer Drugs; 2013 Apr; 24(4):344-54. PubMed ID: 23407059
[TBL] [Abstract][Full Text] [Related]
6. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke.
Turner RJ; Helps SC; Thornton E; Vink R
Brain Res; 2011 Jun; 1393():84-90. PubMed ID: 21466790
[TBL] [Abstract][Full Text] [Related]
7. Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure.
Gabrielian L; Helps SC; Thornton E; Turner RJ; Leonard AV; Vink R
Acta Neurochir Suppl; 2013; 118():201-4. PubMed ID: 23564132
[TBL] [Abstract][Full Text] [Related]
8. The potential for substance P antagonists as anti-cancer agents in brain tumours.
Harford-Wright E; Lewis KM; Vink R
Recent Pat CNS Drug Discov; 2013 Apr; 8(1):13-23. PubMed ID: 23477306
[TBL] [Abstract][Full Text] [Related]
9. The effect of an NK1 receptor antagonist on blood spinal cord barrier permeability following balloon compression-induced spinal cord injury.
Leonard AV; Vink R
Acta Neurochir Suppl; 2013; 118():303-6. PubMed ID: 23564154
[TBL] [Abstract][Full Text] [Related]
10. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
11. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury.
Donkin JJ; Nimmo AJ; Cernak I; Blumbergs PC; Vink R
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1388-98. PubMed ID: 19436311
[TBL] [Abstract][Full Text] [Related]
12. Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.
Yamamoto K; Asano K; Tasaka A; Ogura Y; Kim S; Ito Y; Yamatodani A
Br J Pharmacol; 2014 Jun; 171(11):2888-99. PubMed ID: 24641692
[TBL] [Abstract][Full Text] [Related]
13. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
14. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
Duffy RA; Varty GB; Morgan CA; Lachowicz JE
J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
[TBL] [Abstract][Full Text] [Related]
15. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
16. The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study.
Kwako LE; George DT; Schwandt ML; Spagnolo PA; Momenan R; Hommer DW; Diamond CA; Sinha R; Shaham Y; Heilig M
Psychopharmacology (Berl); 2015 Jan; 232(1):295-304. PubMed ID: 25030801
[TBL] [Abstract][Full Text] [Related]
17. NK1 tachykinin receptor treatment is superior to capsaicin pre-treatment in improving functional outcome following acute ischemic stroke.
Turner RJ; Vink R
Neuropeptides; 2014 Oct; 48(5):267-72. PubMed ID: 25151181
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease.
Thornton E; Vink R
PLoS One; 2012; 7(4):e34138. PubMed ID: 22485158
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.
Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD
AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512
[TBL] [Abstract][Full Text] [Related]
20. Astragaloside IV reduces cerebral edema post-ischemia/reperfusion correlating the suppression of MMP-9 and AQP4.
Li M; Ma RN; Li LH; Qu YZ; Gao GD
Eur J Pharmacol; 2013 Sep; 715(1-3):189-95. PubMed ID: 23747593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
